|
Elena's Biotech Briefing
BIO convention talks centered on FDA wording, biotech dealmaking and Big Pharma’s event role, while lab demand rose for nitrosamine and topical testing.
The top 10 stories from Thu Jun 25, 2026 06:45 AM to Fri Jun 26, 2026 06:46 AM
Generated June 26, 2026 at 6:46 AM
|
|
|
#1 Automating Clinical Decisions For Healthcare System Efficiencies Published 2026-06-26 A persistent gap remains between computer science research and clinical practice, limiting the translation of research advances into routine healthcare decision-making. Covered by: insights.citeline.com |
#2 How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery Published 2026-06-26 iBio says it reached a clinic after adopting an AI-powered discovery platform in 2022, and it describes the outcome as vindication. Covered by: fiercebiotech.com |
#3 RQ Bio raises $115M to advance long-acting antibody prophylaxis for flu: Venture Report Published 2026-06-25 RQ Bio raised $115 million to advance long-acting antibody prophylaxis for influenza, according to a venture report. Covered by: biocentury.com |
#4 Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy Published 2026-06-25 Fosun Pharma co-president Xinli Wang said the company used two recent deals to rapidly expand its Alzheimer’s disease portfolio and build independent U.S. capabilities. Covered by: fiercebiotech.com |
#5 AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS Published 2026-06-25 AFRRI and NIAID designed a proprietary PBI-BM2.5 protocol to evaluate Valion Bio’s entolimod for GI-ARS using validated animal models. Covered by: prnewswire.com |
#6 CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand Published 2026-06-25 CStone Pharmaceuticals appointed Arrotex to handle registration, market access, and commercialization of sugemalimab in Australia and New Zealand under an exclusive agreement. Covered by: prnewswire.com |
#7 Two Claudin 18.2 ADCs Enter Final Stretch Of Global Race With China NDA Published 2026-06-25 Two anti-Claudin 18.2 antibody-drug conjugates are approaching potential world-first approvals in China, with final regulatory steps underway. Covered by: insights.citeline.com |
#8 Labs see rising demand for nitrosamine, topical performance and microbiome testing Published 2026-06-25 BioSpace conference discussions indicate sponsors are seeking earlier safety, quality, and performance data, driving increased demand for nitrosamine analysis, IVRT/IVPT testing, and microbiome database capabilities. Covered by: biospace.com |
#9 AI Framework Surfaces New CAR T Target with Multi‑Cancer Potential Published 2026-06-25 Researchers at the University of Pennsylvania reported in Cell a human-in-the-loop AI framework using LLMs and single-cell RNA-seq data to nominate CAR T cell antigens, tested on skin cancer. Covered by: genengnews.com |
#10 BIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exits Published 2026-06-25 The final day of the BIO International Convention featured discussions on US FDA-related regulatory language, Big Pharma’s role in supporting biotech events, and biotech M&A activity. Covered by: insights.citeline.com |
